Pediatric Research Update: Ethics in Pediatric Obesity Medicine: Adolescent Autonomy and GLP-1 Receptor Agonist Therapy

Article Summary

Can semaglutide support adolescent autonomy? This ethical review challenges weight stigma and examines how GLP-1 therapy, shared decision-making, and comprehensive care can promote informed, patient-centered pediatric obesity treatment.

Read full article

Article Review

Beyond Weight Loss: Ethical Considerations of Semaglutide and Adolescent Autonomy

As pediatric obesity treatment evolves, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including semaglutide, offer promising options while raising questions about adolescent autonomy, informed decision-making, and equitable access. In The Ethics of Wegovy: Promoting Autonomy in Pediatric Care, Ryan and Savulescu ask whether prescribing semaglutide undermines personal responsibility or can strengthen adolescents’ capacity to make informed health decisions. Clinicians must consider not only treatment effectiveness but also effects on physical health, emotional well-being, and developing independence.

Balancing Clinical Benefits with Ethical Responsibilities

The clinical benefits of semaglutide in adolescents with obesity are encouraging. The STEP TEENS trial demonstrated a mean BMI reduction of 16.1% with semaglutide, compared with a 0.6% increase with placebo over 68 weeks. Yet effective treatment involves more than improving BMI. Discussions with patients and families should address adverse effects, nutritional concerns, treatment burden, long-term safety during a period of growth and identity formation, and possible weight regain after discontinuation. The authors also caution that adolescents may be vulnerable to misuse of these medications and to disordered eating, and recommend assessing this risk before prescribing and monitoring for it during treatment. Medication should be incorporated as an adjunct to comprehensive care that includes nutrition counseling, physical activity, behavioral health support when needed, and family involvement. This approach aligns with the American Academy of Pediatrics’ clinical practice guideline, which recommends offering appropriate pharmacotherapy to eligible adolescents aged 12 years and older as an adjunct to health behavior and lifestyle treatment.

Challenging the Idea of an “Easy Way Out”

The authors challenge the “argument from virtue”: the belief that medication prevents adolescents from developing self-discipline, perseverance, or responsibility and makes weight loss less meaningful than lifestyle change alone. Obesity is a complex chronic disease shaped by genetics, biology, environment, and social determinants of health; treatment success should not be judged by how difficult weight loss is to achieve. Many families pursue nutrition, physical activity, and behavioral changes without sufficient improvement. Framing medication as an undeserved “easy way out” can reinforce weight stigma and feelings of failure. Pharmacotherapy should instead be viewed as an evidence-based tool that supports health without diminishing personal responsibility.

Supporting Adolescent Autonomy Through Shared Decision-Making

Semaglutide may support autonomy when adolescents participate meaningfully in treatment decisions. Adolescence is a critical period for developing independence and decision-making skills. Parents and caregivers remain essential, but adolescents’ concerns, preferences, and goals should be heard and respected. Clinicians can explain options in understandable language, discuss benefits and risks, invite questions, obtain parental consent, and seek the adolescent’s informed assent. Respecting autonomy also means allowing space for concerns about medication, side effects, and effects on daily life rather than allowing parental expectations or societal pressures to determine the plan. Shared decision-making helps adolescents become active participants in their healthcare.

Health Equity and Access to Treatment

Equitable access is another ethical concern. High medication costs, insurance restrictions, geographic barriers, and limited pediatric obesity services may prevent eligible adolescents from receiving treatment. These barriers are especially consequential in rural and underserved communities, where registered dietitians, behavioral health specialists, and multidisciplinary programs may already be scarce. My work with an underserved population has reinforced that an effective therapy is not truly accessible if families cannot afford it, secure coverage, travel to appointments, or maintain follow-up. Clinicians must advocate for equitable access while developing practical, sustainable approaches responsive to the communities they serve.

Critical Appraisal and Implications for Practice

A key strength of the article is its focus beyond clinical effectiveness to the ways treatment recommendations may shape adolescents’ autonomy and self-worth. The authors challenge moral judgments surrounding obesity treatment and keep health as the central goal. However, this is a philosophical and narrative analysis rather than an original clinical study. Research is needed to understand how adolescents experience pharmacotherapy, participate in decisions, and perceive effects on emotional well-being. The authors recommend offering semaglutide only after lifestyle interventions have failed or are unsuitable; this position differs from the 2023 AAP Clinical Practice Guideline, which supports individualized, timely treatment rather than requiring prolonged unsuccessful lifestyle intervention. Studies that include adolescents from diverse backgrounds are essential to clarify preferences, long-term outcomes, and barriers to care.

Conclusion

Ryan and Savulescu argue that choosing Semaglutide is not a moral failure or an “easy way out,” and that, when prescribed with appropriate support, it can strengthen rather than undermine adolescent autonomy. For pediatric obesity clinicians, responsible care extends beyond prescribing medication or lowering BMI: it requires listening to adolescents, involving them in decisions, supporting families, and addressing obesity’s emotional and social burdens. Compassionate, respectful, and equitable care should empower each adolescent with the knowledge, confidence, and support to make informed decisions and build a healthier future.